Codexis (CDXS) Cash from Financing Activities (2010 - 2026)
Codexis (CDXS) recorded quarterly Cash from Financing Activities of -$14000.0 in Q1 2026, down 107.78% quarter-over-quarter from $180000.0 in Q4 2025, and down 101.29% on a YoY basis from $1.1 million in Q1 2025.
Codexis (CDXS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Codexis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 101.29% year-over-year to -$14000.0; the TTM figure through Mar 2026 stood at $26.8 million (down 17.0% YoY), while the FY2025 annual figure was $27.9 million, down 53.85% from the prior year.
- Cash from Financing Activities was -$14000.0 for Q1 2026 at Codexis, down from $180000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $30.3 million in Q3 2024 to a low of -$1.3 million in Q1 2022.
- Historically, Cash from Financing Activities has averaged $6.0 million across 5 years, with a median of $286000.0 in 2022.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 7629.41% in 2022, then jumped 28161.11% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $339000.0 in 2022, then plunged by 131.86% to -$108000.0 in 2023, then surged by 1148.15% to $1.1 million in 2024, then sank by 84.1% to $180000.0 in 2025, then sank by 107.78% to -$14000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$14000.0 (Q1 2026), $180000.0 (Q4 2025), and -$111000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Codexis | 226.01 Mn | 160.87 Mn | 13.18 Mn | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Sep 30, 2025 | -111,000.00 |
| Sep 30, 2025 | -111,000.00 |
| Jun 30, 2025 | 26.77 Mn |
| Jun 30, 2025 | 26.77 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 30.31 Mn |
| Sep 30, 2024 | 30.31 Mn |
| Jun 30, 2024 | -197,000.00 |
| Jun 30, 2024 | -197,000.00 |
| Mar 31, 2024 | 29.28 Mn |
| Mar 31, 2024 | 29.28 Mn |
| Sep 30, 2023 | -108,000.00 |
| Sep 30, 2023 | -108,000.00 |